Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 12Carcinoma, Non-Small-Cell Lung 8Ovarian Neoplasms 6Fallopian Tube Neoplasms 5Lung Neoplasms 4Stomach Neoplasms 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Endometrial Neoplasms 3Carcinoma, Ovarian Epithelial 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Inflammatory Breast Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Ductal, Breast 2Adenocarcinoma Of Esophagus 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1The Neoadjuvant Therapy 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Stage IIIB or IV Non-Small Cell Lung Cancer 1Seminoma 1Recurrence 1Primary Malignant Neoplasm of Ovary 1Peripheral Nervous System Diseases 1Pancreatic Neoplasms 1Neoplasms, Cystic, Mucinous, and Serous 1Neoplasm Metastasis 1

Interventions

dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Taxes 1Ranitidine 1Paclitaxel 1Famotidine 1Diphenhydramine 1Dexamethasone 1Cimetidine 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Breast Carcinoma In Situ × Paclitaxel × Clear all
NCT04862585 2025-08-20

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Ohio State University Comprehensive Cancer Center

Phase 2/3 Completed
130 enrolled 8 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡